PTX Stock Overview
A clinical stage oncology company, develops novel drugs for the treatment of various cancers in Australia.
Snowflake Score | |
---|---|
Valuation | 2/6 |
Future Growth | 0/6 |
Past Performance | 0/6 |
Financial Health | 6/6 |
Dividends | 0/6 |
Prescient Therapeutics Limited Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | AU$0.042 |
52 Week High | AU$0.10 |
52 Week Low | AU$0.037 |
Beta | 1.22 |
11 Month Change | 0% |
3 Month Change | -10.64% |
1 Year Change | -30.00% |
33 Year Change | -77.30% |
5 Year Change | 5.00% |
Change since IPO | -99.94% |
Recent News & Updates
Here's Why We're Not Too Worried About Prescient Therapeutics' (ASX:PTX) Cash Burn Situation
Jul 05We Think Prescient Therapeutics (ASX:PTX) Can Afford To Drive Business Growth
Mar 12We're Not Very Worried About Prescient Therapeutics' (ASX:PTX) Cash Burn Rate
Nov 14Recent updates
Here's Why We're Not Too Worried About Prescient Therapeutics' (ASX:PTX) Cash Burn Situation
Jul 05We Think Prescient Therapeutics (ASX:PTX) Can Afford To Drive Business Growth
Mar 12We're Not Very Worried About Prescient Therapeutics' (ASX:PTX) Cash Burn Rate
Nov 14Companies Like Prescient Therapeutics (ASX:PTX) Are In A Position To Invest In Growth
Aug 01Shareholders Would Not Be Objecting To Prescient Therapeutics Limited's (ASX:PTX) CEO Compensation And Here's Why
Nov 22Here's Why We're Not Too Worried About Prescient Therapeutics' (ASX:PTX) Cash Burn Situation
Oct 19Prescient Therapeutics (ASX:PTX) Is In A Strong Position To Grow Its Business
Jun 19Prescient Therapeutics (ASX:PTX) Is In A Strong Position To Grow Its Business
Feb 27We Think Shareholders Are Less Likely To Approve A Large Pay Rise For Prescient Therapeutics Limited's (ASX:PTX) CEO For Now
Nov 05We Think Prescient Therapeutics (ASX:PTX) Can Easily Afford To Drive Business Growth
Aug 26Prescient Therapeutics (ASX:PTX) Is In A Good Position To Deliver On Growth Plans
May 08Does Prescient Therapeutics' (ASX:PTX) CEO Salary Compare Well With The Performance Of The Company?
Jan 11Shareholder Returns
PTX | AU Biotechs | AU Market | |
---|---|---|---|
7D | 2.4% | -0.7% | 2.6% |
1Y | -30.0% | 14.7% | 10.6% |
Return vs Industry: PTX underperformed the Australian Biotechs industry which returned 14.7% over the past year.
Return vs Market: PTX underperformed the Australian Market which returned 10.6% over the past year.
Price Volatility
PTX volatility | |
---|---|
PTX Average Weekly Movement | 8.5% |
Biotechs Industry Average Movement | 11.7% |
Market Average Movement | 8.1% |
10% most volatile stocks in AU Market | 16.8% |
10% least volatile stocks in AU Market | 3.4% |
Stable Share Price: PTX has not had significant price volatility in the past 3 months.
Volatility Over Time: PTX's weekly volatility (8%) has been stable over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
1986 | n/a | Steven Yatomi-Clarke | ptxtherapeutics.com |
Prescient Therapeutics Limited, a clinical stage oncology company, develops novel drugs for the treatment of various cancers in Australia. Its lead drug candidate is PTX-200, which is in Phase 2a clinical trial for HER2-negative breast cancer, Phase IB/2 clinical trial in relapsed and refractory AML, and Phase 1b in recurrent or persistent platinum-resistant ovarian cancer; and PTX-100, a RhoA inhibitor, for hematological and solid malignancies that focuses on cancers with Ras and RhoA mutations. It has a strategic collaboration with The University of Texas MD Anderson Cancer Center to develop blood cancer binder for OmniCAR.
Prescient Therapeutics Limited Fundamentals Summary
PTX fundamental statistics | |
---|---|
Market cap | AU$33.82m |
Earnings (TTM) | -AU$7.74m |
Revenue (TTM) | AU$3.11m |
10.9x
P/S Ratio-4.4x
P/E RatioIs PTX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
PTX income statement (TTM) | |
---|---|
Revenue | AU$3.11m |
Cost of Revenue | AU$0 |
Gross Profit | AU$3.11m |
Other Expenses | AU$10.86m |
Earnings | -AU$7.74m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
Earnings per share (EPS) | -0.0096 |
Gross Margin | 100.00% |
Net Profit Margin | -248.74% |
Debt/Equity Ratio | 0% |
How did PTX perform over the long term?
See historical performance and comparison